ExodusPoint Capital Management LP Has $3.94 Million Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

ExodusPoint Capital Management LP decreased its stake in Scholar Rock Holding Co. (NASDAQ:SRRK) by 41.8% in the fourth quarter, HoldingsChannel reports. The firm owned 91,230 shares of the company’s stock after selling 65,611 shares during the period. ExodusPoint Capital Management LP’s holdings in Scholar Rock were worth $3,943,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares during the period. Global Retirement Partners LLC raised its position in Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares during the period. Nisa Investment Advisors LLC lifted its stake in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after acquiring an additional 1,031 shares in the last quarter. Amalgamated Bank boosted its position in Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after acquiring an additional 620 shares during the period. Finally, KBC Group NV purchased a new position in Scholar Rock during the 4th quarter valued at about $131,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Trading Down 12.4 %

Shares of NASDAQ SRRK opened at $26.90 on Monday. The business has a 50 day simple moving average of $36.31 and a 200 day simple moving average of $34.01. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $46.98. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -11.45 and a beta of 0.56. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.

Insider Transactions at Scholar Rock

In other news, CEO Jay T. Backstrom sold 22,308 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $986,013.60. Following the transaction, the chief executive officer now owns 330,363 shares of the company’s stock, valued at approximately $14,602,044.60. This represents a 6.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jing L. Marantz sold 5,655 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the sale, the insider now directly owns 67,200 shares of the company’s stock, valued at $2,970,240. The trade was a 7.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 299,772 shares of company stock worth $11,245,798 in the last 90 days. 19.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Wedbush restated an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.